Quantcast

Industry news that matters to you.  Learn more

Discovery and Validation of 13 Diabetes Biomarkers to be Commercialized

After three years of collaborative research involving patients from The Busselton Health Study, drug discovery company Proteomics International announced the identification and analytical validation of 13 protein biomarkers for a significant complication of diabetes – diabetic nephropathy (kidney disease). In a presentation at the Human Proteome Organisation’s World Congress in Sydney, Australia, Dr Richard Lipscombe, Managing Director of Proteomics International, revealed the findings that could benefit many of the 250 million people worldwide who have diabetes.